SCHEMBL6813982

SCHEMBL6813982

COc1ccc(C(C)(C(F)(F)F)C(F)(F)F)cc1C=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.46
TSHR P16473 2/20 0.46
KDM4E B2RXH2 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
LMNA P02545 2/20 0.41
HPGD P15428 1/20 0.41
TUBB1 Q9H4B7 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
PRKDC P78527 2/20 0.39
ERN1 O75460 5/20 0.38
TLR2 O60603 1/20 0.37
TLR1 Q15399 1/20 0.37
TLR6 Q9Y2C9 1/20 0.37
AOX1 Q06278 1/20 0.37
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 2/20 0.36
NQO2 P16083 1/20 0.35
NR3C1 P04150 1/20 0.35
NR3C2 P08235 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1186123 0.88 ALDH1A1 (0.50) ALDH1A1TSHRKDM4ETDP1LMNA
SCHEMBL3650254 0.87 ALDH1A1 (0.46) ALDH1A1TSHRKDM4ETDP1LMNA
SCHEMBL7133759 0.87 ALDH1A1 (0.48) ALDH1A1TSHRKDM4ETDP1LMNA
SCHEMBL7137814 0.85 ALDH1A1 (0.47) ALDH1A1TSHRKDM4ETDP1LMNA
SCHEMBL7135494 0.85 ALDH1A1 (0.47) ALDH1A1TSHRKDM4ETDP1LMNA
SCHEMBL4186655 0.83 ALDH1A1 (0.52) ALDH1A1TSHRKDM4ETDP1LMNA
SCHEMBL31738417 0.83 ALDH1A1 (0.52) ALDH1A1TSHRKDM4ETDP1LMNA
SCHEMBL7137868 0.83 ALDH1A1 (0.44) ALDH1A1TSHRKDM4ETDP1TUBB1
SCHEMBL14242951 0.81 ALDH1A1 (0.50) ALDH1A1TSHRKDM4ETDP1LMNA
SCHEMBL7616411 0.80 ALDH1A1 (0.48) ALDH1A1TSHRKDM4ETDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1114817-B1 Substituted benzylamino piperidine compounds PFIZER (US) 2004-01-21 EP disclosed
US-6506775-B1 Treatment of a gastrointestinal disorder; a central nervous system (CNS) adverse conditions caused by Heliobacter pylori; or angiogenesis especially CNS disorders in a mammalian subject, especially humans. PFIZER INC 2003-01-14 US disclosed
US-6329396-B1 TREATMENT OF GASTROINTESTINAL DISORDERS CENTRAL NERVOUS SYSTEM (CNS) DISORDERS; INFLAMMATORY DISEASE; EMESIS; URINARY INCONTINENCE; PAIN; MIGRAINE; SUNBURN; DISEASES, DISORDERS AND ADVERSE CONDITIONS CAUSED BY HELIOBACTER PYLORI; OR PFIZER INC. 2001-12-11 US disclosed
EP-1114817-A1 Substituted benzylamino piperidine compounds PFIZER INC. (US) 2001-07-11 EP disclosed
EP-0861235-A1 SUBSTITUTED BENZYLAMINOPIPERIDINE COMPOUNDS PFIZER INC. (US) 1998-09-02 EP disclosed
WO-1997008144-A1 SUBSTITUTED BENZYLAMINOPIPERIDINE COMPOUNDS PFIZER PHARMACEUTICALS INC. (JP) 1997-03-06 WO disclosed